Materials and Methods
This retrospective study included 12 patients who presented with RHS between March 2006 and October 2014. Patients were diagnosed with Ramsay Hunt syndrome if they had peripheral facial palsy and vesicles around the ear. Data recorded included sex, age, time from the first onset to initial treatment and clinical outcomes. The HouseBrackmann scale was used to assess initial facial nerve dysfunction and final facial nerve impairment. All patients underwent electroneurography (ENoG) 3 days after onset of palsy and all were followed up with electromyography (EMG) 3 weeks after the onset. Patients were followed up until recovery or for 6 months. Recovery was defined as attainment of House-Brackmann grade I or II.
Pure tone audiometry and neurology consultation was performed in all patients before treatment to assess the eight and other cranial nerve functions. Magnetic resonance imaging (MRI) was also performed.
All patients had low-salt diet. Patients were treated with oral steroids (1 mg/kg) by tapering dose regimen. Oral acyclovir (4000 mg/d for 7 days) was combined with oral steroids. Diabetic patients received the same dose of steroids under the medical care of an endocrinologist.
Results
There were seven male and five female patients in this retrospective study with a median age of 59 (range: 21 to 68) years. All patients admitted to our clinic within 2-5 days after the onset of the symptoms and received the treatment protocol. The median initial House-Brackmann grade was 4.5, while it was 2.33 after the treatment in all patients. Hearing loss and rotational vertigo were seen in six patients. Patients' characteristics are shown in Table 1 .
Overall recovery rate was 75% in this study. Recovery rate was lower in patients with a an ENoG of >90% compared with ENoG <90%. Similarly, worse initial facial palsy was associated with lower recovery rate. Initial House-Brackman grade V or more had lower recovery rates. Recovery rate was 83.3% in patients with HouseBrackmann grade ≤4; however, recovery rate was 33.3% in grades ≥V. Five patients had comorbid diseases (diabetes mellitus, hypertension). Patients with comorbid disease(s) had also lower recovery rates (Table 2) .
Discussion
The standard treatment of RSH syndrome is corticosteroid and antiviral therapy. Corticosteroid therapy relieves pain, reduces vertigo, decreases the incidence of postherpetic neuralgia. It also reduces facial nerve inflammation and edema. Acyclovir, a synthetic acyclic purine nucleoside analog, is a selective inhibitor of herpes simplex virus types 1 and 2. [6] Combined therapy is the treatment of choice in RSH syndrome. Uscategui et al. demonstrated a statistically significant difference between combined acyclovir-corticosteroid therapy and treatment with corticosteroids alone. [7] Similarly, Kinishi et al. reported that median recovery rate from facial palsy was 62% in patients treated with corticosteroids alone, however, with both acyclovir and steroid therapy, the receive rate was 90 percent. [6] The recovery rate was 84% in the study by Lee et al. [8] In our study, we treated our patients with combined therapy and the overall recovery rate was 75 percent.
We found that initial palsy episodes with lower grades of palsy were associated with a higher recovery rate. The median initial House-Brackmann grade was 4.5. HouseBrackmann grade was 2.33 after the treatment. Recovery rate was lower in patients with grade V or more compared with mild cases. Similar to our results, Ko et Table 2 . Recovery rates of patients after treatment.
Journal of Medical Updates
Zainine et al. found that incomplete paralysis had higher recovery rates. [4, 9] Coulson et al. also reported that improvement was less likely for patients who initially had higher House-Brackmann scores. [10] Patients with comorbid disease(s) had poorer prognoses than those without comorbid disease(s). This can be attributable to the presence of diabetic neuropathy. In our study, comorbid disease had lower recovery rate. Yeo et al. found that recovery rates were significantly lower in patients with comorbid disease(s). [11] Electroneurography is usually used to measure nerve injury and disease progression in facial palsy. Electroneurography is generally effective when performed more than 3 days after the onset of palsy, when neural damage can be accurately determined. [8] We performed EnoG, 3 days after the onset and found a relationship between ENoG results and patient prognosis. Anpalahan et al. reported that ENoG correctly predicted recovery in 98% of their patients when the neural response of the affected side was more than 25% of the unaffected side. [12] Based on the data of Byun et al., non-recovery is predicted in patients with ENoG values greater than 78% in RHS. [13] Morishima et al. also reported the prognostic value of ENoG in RHS. [14] 
Conclusion
Combined treatment in RHS is the treatment of choice. Patients with comorbid disease(s) in RHS have poorer prognosis. In addition, initial House-Brackmann grades of ≥V and worse ENoG response results in lower recovery rates.
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